HC Wainwright & Co. Reiterates Neutral on Reneo Pharmaceuticals, Maintains $1.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Neutral rating on Reneo Pharmaceuticals (NASDAQ:RPHM), with a maintained price target of $1.5.
May 14, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Reneo Pharmaceuticals maintains a Neutral rating and a price target of $1.5 by HC Wainwright & Co., indicating a stable outlook without immediate growth expectations.
The reiteration of a Neutral rating with a maintained price target suggests that the analyst sees no immediate catalysts that would significantly change the company's valuation in the short term. This outlook implies a stable but not particularly growth-oriented view on the stock, which could lead to a neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100